SciHub
文献互助
期刊查询
一搜即达
科研导航
即时热点
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
学医的杨同学
Lv4
1
530 积分
2024-12-20 加入
最近求助
最近应助
互助留言
DLBCL: Who is high risk and how should treatment be optimized?
5小时前
待确认
DLBCL: Who is high risk and how should treatment be optimized?
5小时前
已关闭
DLBCL: who is high risk and how should treatment be optimized?
5小时前
已关闭
DLBCL: Who is high risk and how should treatment be optimized?
5小时前
已关闭
Gene-Based Marker to Differentiate Among B, A, and R Lines in Hybrid Production of Rapeseed Ogura System
5小时前
已采纳
Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
5小时前
已采纳
没有进行任何互助留言
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论
DLBCL: Who is high risk and how should treatment be optimized?
Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
皖公网安备34019202002308
